UNSPSC 51172120: Ciclactate

This classification denotes an antispasmotic agent with the molecular formula C12H22O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MYS6082G8G, chemically known as 3,3,5-trimethylcyclohexyl lactate. but generally known as ciclactate, which bears US NIH Compound Identifier 193969. European Medicines Agency schedules Ciclactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06233MIG.

UNSPSC 51172120 Ciclactate is a Commodity code that covers drug-testing reagents and screening supplies used in specimen analysis. State and local governments procuring under this code are buying immunoassay screening materials, confirmatory testing supplies (LC/MS/MS and GC/MS), and ancillary testing methodologies to support criminal justice supervision, employee drug screening, and healthcare compliance programs. The issuing bodies include county community supervision departments, state health and human services agencies, and cooperative purchasing alliances serving multi-state networks of public health, corrections, and institutional buyers. Collin County Community Supervision and Corrections Department and the Texas Health and Human Services Commission represent the primary recent activity, with the county seeking specimen collection and drug testing services that explicitly require SAMHSA, TX DPS, or CAP certified lab providers and immunoassay screening with confirmation capability.

Recent activity concentrates in Texas, where Collin County posted RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 over two years plus three optional one-year renewals, covering approximately 25,031 annual tests across five-panel and six-panel screens with oral fluid and hair testing options. The Texas HHS Commission simultaneously issued RFI HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling upstream state interest in pharmaceutical sourcing and supply chain optimization that may affect testing reagent procurement pathways. A multistate cooperative purchasing opportunity through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted January 20, 2026 (due March 26, 2026) for generic pharmaceuticals and OTC products distributed through participating state and local facilities in Minnesota and Oregon, demonstrating broader geographic demand for pharmaceutical sourcing coordination among state procurement offices. Collin County's award date is anticipated August 10, 2026, with contract performance commencing September 1, 2026.